Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2024 | What is the optimal duration of treatment of enfortumab vedotin in urothelial carcinoma?

Jonathan Rosenberg • 16 Sep 2024
ESMO 2024
Genitourinary Cancer Urothelial Carcinoma Antibodies Enfortumab vedotin Pembrolizumab

Jonathan Rosenberg, MD, Memorial Sloan Kettering Cancer Center, New York, NY, gives an overview of findings from a study assessing the optimal duration of enfortumab vedotin treatment for patients with urothelial carcinoma. Patients receiving 8.5 months worth of treatment were found to have good progression-free survival. However, this was in heavily pretreated patients receiving enfortumab vedotin monotherapy, and more research is needed in first-line settings. This interview took place at the European Society for Medical Oncology (ESMO) 2024 Congress in Barcelona, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Jonathan Rosenberg

The future of antibody-drug conjugates in urothelial carcinoma
1:39
The future of antibody-drug conjugates in urothelial carcinoma
Jonathan Rosenberg • 16 Sep 2024
NKT2152, an oral HIF-2α inhibitor, in pre-treated advanced clear cell renal carcinoma
1:31
NKT2152, an oral HIF-2α inhibitor, in pre-treated advanced clear cell renal carcinoma
Jonathan Rosenberg • 16 Sep 2024
5-year follow-up of EV and pembrolizumab for la/mUC in the EV-103 trial
1:30
5-year follow-up of EV and pembrolizumab for la/mUC in the EV-103 trial
Jonathan Rosenberg • 16 Sep 2024
Phase I trial of BL-B01D1, an EGFR x HER3 bispecific ADC, in urothelial carcinoma UC
1:30
Phase I trial of BL-B01D1, an EGFR x HER3 bispecific ADC, in urothelial carcinoma UC
Jonathan Rosenberg • 16 Sep 2024

Related Videos

Current and emerging systemic strategies in biochemically relapsed prostate cancer
2:45
Current and emerging systemic strategies in biochemically relapsed prostate cancer
Ashwin Sachdeva • 16 May 2026
How has SABR improved radiotherapy practice in kidney cancer?
1:06
How has SABR improved radiotherapy practice in kidney cancer?
Shankar Siva • 16 May 2026
Which patients with kidney cancer may benefit from SABR treatment?
1:58
Which patients with kidney cancer may benefit from SABR treatment?
Shankar Siva • 16 May 2026
Management of brain metastasis in patients with poor-risk testicular cancer
1:03
Management of brain metastasis in patients with poor-risk testicular cancer
Darren Feldman • 30 May 2026
The content of VJOncology is intended for healthcare professionals